Status:
COMPLETED
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine
Lead Sponsor:
Mclean Hospital
Collaborating Sponsors:
University of Minnesota
Conditions:
Schizophrenia
Bipolar Disorder
Eligibility:
All Genders
34-62 years
Phase:
EARLY_PHASE1
Brief Summary
The purpose of this study is to assess the efficacy of d-cycloserine (DCS) as an augmentation strategy in two psychotic patients with a triplication (4 copies) of the glycine decarboxylase (GLDC) gene...
Detailed Description
Multiple rare structural variants of relatively recent evolutionary origin are recognized as important risk factors for schizophrenia (SZ) and other neurodevelopmental disorders (e.g., autism spectrum...
Eligibility Criteria
Inclusion
- Carriers of a triplication in the glycine decarboxylase gene
Exclusion
- Not carriers of a triplication in the glycine decarboxylase gene
Key Trial Info
Start Date :
September 27 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2017
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT02304432
Start Date
September 27 2015
End Date
July 31 2017
Last Update
September 19 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.